Fecal calprotectin: current and future perspectives for inflammatory bowel disease treatment
| Autor: | Linda Ceccarelli, Santino Marchi, Lorenzo Bertani, E. Albano, Giovanni Baiano Svizzero, Francesco Costa, Massimo Bellini, Federico Zanzi, Maria Gloria Mumolo, G. Tapete |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
treat-to-target
medicine.medical_specialty Reduced risk Disease Inflammatory bowel disease Gastroenterology Feces 03 medical and health sciences fluids and secretions 0302 clinical medicine inflammatory bowel disease Internal medicine medicine Humans Crohn's disease fecal calprotectin ulcerative colitis Intestinal Mucosa Hepatology business.industry Colonoscopy Inflammatory Bowel Diseases medicine.disease 030220 oncology & carcinogenesis Mucosal healing 030211 gastroenterology & hepatology Calprotectin business Leukocyte L1 Antigen Complex Biomarkers |
| Zdroj: | European Journal of Gastroenterology & Hepatology. 32:1091-1098 |
| ISSN: | 0954-691X |
| DOI: | 10.1097/meg.0000000000001731 |
| Popis: | Fecal calprotectin has been widely studied in inflammatory bowel disease (IBD) under clinical and therapeutic settings. It showed a good correlation with clinical, endoscopic, and histologic findings. For these reasons, fecal calprotectin is currently one of the most useful tools in IBD care, both in diagnosis and in clinical management. The development of biologic drugs allowed a deeper control of disease, which sometimes reaches histological healing; this is associated with a reduced risk of relapses and complications. The management of IBD treatment is currently carried out with a treat-to-target approach, and mucosal healing is considered at present to be the optimal therapeutic target, but the future is going through histologic remission. Fecal calprotectin is probably the best marker of mucosal healing, but it is correlated also with histologic remission: moreover, it has been recently studied as a possible therapeutic target in the CALM study. We carried out a comprehensive literature review in order to evaluate the role of fecal calprotectin at present and in the future in the management of IBD therapies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|